Surrozen, Inc.

NASDAQ:SRZN

Biotechnology

Healthcare
$31.74 -4.74%

-$1.14 today

Market cap
$237.33M
Beta
0.51
P/E (TTM)
-0.7
EPS (TTM)
-$31.29
52W Low $8.00High $35.00

Volume 0.31M

Average 0.11M

SRZN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Surrozen, Inc.NASDAQ: SRZN

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 98.7%

Gross margin was 98.7% in Q1 FY2026, down 1.3 pp from a year earlier. On a trailing-twelve-month basis it was 99.1%, up 2.4 pp year over year. Over 3 fiscal years it widened by 10.7 pp.

Context

  • Gross margin widened in 1 of the last 2 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
98.7%-1.3 pp QoQ
Last fiscal yearDec 2025
84.6%-15.4 pp YoY
LTMMar 2026
99.1%+2.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.3 pp——
1 year-15.4 pp——
3 years+10.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
84.6%
Year-over-year change
-15.4pp

Gross Margin vs competitors

How SRZN compares with its peers on the latest reported figures

  • SRZN's LTM Mar 2026 gross margin of 99.1% is the highest of the 4 companies compared; the peer median is 49.6%.
  • Its year-over-year change of +2.4 pp is the lowest of 4, against a peer median of +18.6 pp.
  • Over three fiscal years its change of +10.7 pp compares with a peer median of +9.2 pp.
SRZN Competitors Peer median
Gross Margin for SRZN and competitors
Company Period LTM level YoY 3-year change
SRZNSurrozen, Inc.LTM Mar 202699.1% +2.4 pp+10.7 pp
AGENAgenus Inc.LTM Mar 202652.1% +86.4 pp+130.9 pp
IRDOpus Genetics, Inc.LTM Mar 202649.6% +6.6 pp+0.0 pp
SEERSeer, Inc.LTM Mar 202648.3% +18.6 pp+9.2 pp
IMMXImmix Biopharma, Inc.FY2025— ——
GLSIGreenwich LifeSciences, Inc.FY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
TILInstil Bio, Inc.FY2025— ——
Peer median (excluding SRZN) 49.6%+18.6 pp+9.2 pp

Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue012.5M010.66M3.48M
Cost of Revenue3.3M3.27M27.23M0537K
Gross Profit(3.3M)9.23M(27.23M)10.66M2.94M
Gross Margin—73.8%—100.0%84.6%
Research & Development36.88M37.01M27.23M21.13M29.37M
Selling, General & Admin14.21M19.83M15.8M15.06M16.2M
Operating Expenses51.09M53.57M18.55M36.19M45.03M
Depreciation & Amortization3.3M1.96M1.91M1.44M537K
EBITDA(51.35M)(34.05M)(41.13M)(62.12M)(241.49M)
EBITDA Margin—-272.4%—-583.0%-6945.3%
Operating Income(54.39M)(44.34M)(45.78M)(25.54M)(42.09M)
Operating Margin—-354.7%—-239.7%-1210.6%
Interest Income72K781K2.34M1.69M3.02M
Interest Expense00000
Other Income / Expenses(257K)8.34M2.74M(38.03M)(199.93M)
Income Before Tax(54.65M)(36M)(43.04M)(63.56M)(242.03M)
Pre-Tax Margin—-288.0%—-596.6%-6960.8%
Income Tax Expense00000
Net Income(52.51M)(36M)(43.04M)(63.56M)(242.03M)
Net Margin—-288.0%—-596.6%-6960.8%
EPS (Basic)(23.40)(15.55)(21.33)(21.67)(32.37)
EPS (Diluted)(23.40)(15.55)(21.33)(21.67)(32.37)
Weighted Avg Shares2.34M2.31M2.02M2.93M7.48M
Weighted Avg Shares (Diluted)2.34M2.31M2.02M2.93M7.48M

Surrozen, Inc.

NASDAQ:SRZN

Intrinsic Alpha fair value

Locked

Current Price

$31.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.